94 results about "Glycan metabolism" patented technology

The invention discloses a health-care beverage of guava. The health-care beverage is characterized by comprising the following substances and materials in parts by weight: 30-50 parts of guava, 20-40 parts of bitter gourd, 10-30 parts of Chinese yam, 20-40 parts of folium mori and 5-20 parts of American ginseng. The health-care beverage can be made into dosage forms of tablets, capsules, granules, tea bags and the like; the health-care beverage tastes good, has the original flavor, has the pleasant tea fragrance, is applicable for long-term drinking of glycosuria patients, has the functions of conditioning the insulin secretion and promoting the glycometabolism and fat metabolism, and is capable of conditioning the physiological functions of glycosuria patients, recovering the normal functions of the spleen and stomach and achieving the functions of blood sugar reduction, fat reduction, and glycosuria adjuvant therapy; and when being drunk or taken by ordinary people, the health-care beverage also has the functions of promoting the human body conditioning ability and ensuring the health.

Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid / glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2α,3β,12β-trihydroxydammar-20(22)-E,24-diene-3-O-[β-D-glucopyranosyl-(1→)-β-D-glucopyranoside], named Damulin A, and a novel compound 2α,3β,12β-trihydroxydammara-20,24-diene-3-O-[β-D-glucopyranosyl-(1→)-β-D-glucopyranoside], named Damulin B. Herein, the contents of damulin A and damulin B (as active indicator ingredients for AMPK activation) can be increased by treating a Gynostemma pentaphyllum extract with high temperature / high pressure. Accordingly, the novel Gynostemma pentaphyllum extract with a significantly increased AMPK activating capability can be used for improving or treating metabolic syndrome, such as obesity, diabetes, and hyperlipidaemia.

Provided is a construction method of an escherichia coli genetically engineered bacteria producing succinic acid by xylose metabolism and the method for producing succinic acid by fermentation using the bacteria. The ATP biosynthesis pathway of escherichia coli is modified by means of molecular biology and the enzyme activity related to the pathway is over-expressed; thus the total ATP amount within escherichia coli cells is effectively increased such that the recombinant escherichia coli is able to grow using xylose metabolism, and the succinic acid synthesis efficiency is thereby significantly improved.

The invention provides a genetic engineering bacterium strain for producing succinic acid. The genetic engineering bacterium strain is named as Escherichia coli BA016, the preserving number registration number CCTCC NO is M 2012350. The invention further provides a construction method of the strain and a method for producing succinic acid by fermentation, recombinant escherichia coli can grow by glucose metabolism through joint excessive expression of exogenous pyruvic carboxylase and nicotinic acid ribose phosphate transferase, generation of by-product pyruvic acid is reduced, and accordingly the yield and production intensity of succinic acid are greatly improved.

The present invention relates to a fluorescent dye-labeled glucose analog, and a synthesis method and usage of the same, and more particularly, to novel glucose α and β anomers in which a fluorescent dye is labeled by O-1-glycosylation, an asymmetric synthesis method of the anomers, a molecular bioimaging method of the anomers, and a screening method of curing or preventing drugs for diseases related to glucose metabolism.

The invention provides a CectGPDH2 gene and an application thereof in increase of fatty acid content. The nucleotide sequence of the CectGPDH2 gene is shown as SEQ NO.1. The gene comes from Chlorella ellipsoidea and encodes GPDH, wherein the GPDH participates in shuttle of the mitochondrion G3P (glycerol-3-phosphate), provides electrons for respiratory chains, is a key enzyme for G3P synthesis, is one of the key enzymes for connecting glucose metabolism with lipid metabolism and plays an important role in lipid synthesis and energy metabolism in plants. The total fatty acid content of seeds of Arabidopsis thaliana and rape genetically modified with the gene can be increased obviously, and the gene can be used for increasing the oil content of plant cells and the content of linoleic acid (C18:2) and eicosenoic acid (C20:1) in the plants and has good application prospect.

The invention belongs to the technical field of biological engineering, relates to a gene engineering bacterial strain generating succinic acid and a method of producing succinic acid by fermentation of the gene engineering bacterial strain, particularly to a gene engineering bacterial strain generating succinic acid, namely Escherichia coli BA103, by high-efficiency use of glucose, a construction method of Escherichia coli BA103 and a method of producing succinic acid by Escherichia coli BA103. By expression of an exogenous pyruvate carboxylase, recombinant Escherichia coli can grow by use of glucose metabolism, so that the yield of succinic acid is greatly increased, the generation intensity is greatly improved, and the generation of pyruvic acid as a by-product is reduced.

The invention provides a Cem GPDH (Glycerol-3-phosphate dehydrogenase) gene and an application of the Cem GPDH gene in the aspect of increase of cellular fatty acid content. A nucleotide sequence of the Cem GPDH gene is represented as SEQ ID NO: 1. The gene is derived from Chlorella ellipsoidea, and GPDH is coded. G3P (Glycerol-3-phosphate) synthesized through catalysis by GPDH is an important raw material for synthesis of TAG (triacylglycerol), the enzyme participates in mitochondria G3P shuttle, provides electrons for a respiratory chain, is a key enzyme for G3P synthesis, is one of key enzymes for connecting glycometabolism and lipid metabolism and has an important effect on lipid synthesis and energy metabolism in plants; and besides, the gene can remarkably increase the total fatty acid content of cells when utilized to convert yeast cells, plant cells and microalgae cells.

This invention provides a method for measuring glucose metabolism ability of a subject and a composition that is suitably used in the method. The method for measuring glucose metabolism ability of the present invention is as follows: a method for measuring glucose metabolism ability of a subject, using a composition for measuring glucose metabolism ability, the composition comprising, as an active ingredient, glucose labeled with at least one isotope of C, wherein the glucose is converted in the body into labeled carbon dioxide that is excreted in expired air, the method comprising steps (a) and (b) below:(a) administering the composition to the subject and collecting expired air; and(b) determining the ratio of labeled CO2 amount to unlabeled CO2 amount or the ratio of labeled CO2 amount to total CO2 amount.

The present invention belongs to the technical field of preoperative and postoperative drink and provides preoperative and postoperative solid drink. The preoperative and postoperative solid drink iscomposed of the following components in parts by weight: a total of 40-60 g of one or more of maltodextrin, isomaltulose, crystalline fructose, glucose and sucrose, 0-15 g of glutamine, 0-5 g of arginine, 0.6-0.8 g of sodium citrate dihydrate, 0.1-0.3 g of potassium dihydrogen phosphate, 0.5-0.9 mg of vitamin B1, 0.5-0.6 mg of vitamin B6, 0.4-0.6 [mu]g of vitamin B12, 2-6 mg of nicotinamide, 1-5 mg of zinc, 170-250 mg of taurine, 10-40 mg of inositol, 0-0.05 g of citric acid, 0.001-0.03 g of potassium sorbate and the balance of water. The invention solves problems of body's glucose metabolismdisturbance, imbalance of internal environment steady state, increases of glycogen catabolism and gluconeogenesis, and accelerations of decompositions of proteins and fats caused by a long-term preoperative and postoperative food and drink fasting, insulin resistance caused by a metabolic stress state of patients, and reduced surgical responsiveness and compliance, and increased intraoperative andpostoperative body stress responses not conducive to intraoperative and postoperative capacity management.

The present invention relates to a nucleic acid molecule comprising a chromosomal region contributing to or indicative of hyperlipidemias and / or dyslipidemias or defective carbohydrate metabolism, wherein said nucleic acid molecule is selected from the group consisting of: (a) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, wherein said nucleic acid sequence has one or more mutations having an effect on USFI function; (b) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, wherein said nucleic acid sequence is characterized by comprising a guanine or an adenine residue in position 3966 in intron 7 of the USF1 sequence; and / or (c) a nucleic acid molecule having or comprising the nucleic acid sequence of SEQ ID NO: 1, wherein said nucleic acid sequence is characterized by comprising a cytosine or a thymine residue in position 5205 in, exon 11 of the USF1 sequence; wherein said nucleic molecule extends, at a maximum, 50000 nucleotides over the 5' and / or 3' end of the nucleic acid molecule of SEQ ID NO: 1. The present invention further relates to a diagnostic composition comprising a nucleic acid molecule encoding USF1 or a fragment thereof, the nucleic acid molecule disclosed herein, the vector, the primer or primer pair of the present invention or an antibody specific for USF1. Finally, the present invention relates to the use of the nucleic acid molecule of the invention for the preparation of a pharmaceutical composition for the treatment of hyperlipidemia, dyslipidemia, coronary heart disease, type II diabetes, metabolic syndrome, hypertension or atherosclerosis.

The invention relates to a non-invasive near-infrared light-controlled nano material for treating diabetes mellitus, and claims to protect the application of an up-conversion fluorescence nano material in preparation of a tool for treating diabetes mellitus. The up-conversion fluorescence nano material comprises a rare earth element doped inorganic nano material, a hepatocyte targeting molecule and a water-soluble polymer. The invention discloses a new application of the non-invasive up-conversion fluorescent nano material. An invasive optical fiber does not need to be implanted into an animalthrough an operation during diabetes treatment, near-infrared light with high tissue penetrability is used for exciting an up-conversion nano material in a living body, and light in the near-infraredband is converted into visible light through the up-conversion material so that photosensitive protein is activated, and glucose metabolism related signal pathways in cells are remotely regulated andcontrolled without relying on insulin under the condition of high time-space resolution, glycogen synthesis is promoted, glycogenesis is inhibited, and the blood glucose level is reduced.

The invention discloses a method for quantitative determination of regeneration capability of 1,5-ribulose diphosphate. The method comprises the following steps: selecting the second, the third and the fourth completely spread leaves, performing non-destructive determination on apparent photosynthesis rate, taking a mean value of three leaves to represent the apparent photosynthesis rate PN of the plant; then taking the leave which has measured apparent photosynthesis rate, shearing the leave and fully mixing the leave, taking 0.1 g of the material for enzyme liquid extraction; respectively determining the phosphofructokinase vitality and glucose-6-phosphate dehydrogenase enzyme vitality expressed by the change value at unit volume and unit time in the extracted enzyme liquid, calculating phosphopentose pathway proportion in the glycometabolism according to a formula, and then multiplying by the apparent photosynthesis rate of the plant leave to obtain the regeneration capability of 1,5-ribulose diphosphate. The method can realize rapid quantitative determination of the regeneration capability of 1,5-ribulose diphosphate, and has the advantages of less step, simple calculation, and comparability and reliability of the determination result.

The invention belongs to the field of glucosamine production, and relates to a production method of glucosamine. The production method comprises the steps of: in the glucosamine fermentation process,monitoring at least one of an oxygen consumption rate, an oxidation-reduction potential, acetic acid concentration and a specific carbon dioxide release rate in fermentation liquor on line, and controlling the numerical value within a specific range by stages. According to the method provided by the invention, at least one of the oxygen consumption rate, the oxidation-reduction potential, the acetic acid concentration and the specific carbon dioxide release rate in the fermentation liquor is monitored and controlled on line to feed back process parameters of the regulation and control process,so that the thallus growth requirement can be met, glucosamine metabolic synthesis is effectively promoted, and the conversion rate is increased; and the content and conversion rate of the glucosamine in the obtained fermentation product are both high.

The invention discloses a construction method of an FNDC5 gene knock-out rat model, and an application. The invention discloses two sgRNAs in accordance with a FNDC5 gene of a rat, and a correspondingtarget gene sequence, and the two sgRNAs are respectively designed on FNDC5 genes Intron1 and 3'UTR. The sgRNAs can be applied to construction of a rat animal model having insulin resistance and glycometabolism disorders. The invention provides a simple reliable economic animal model making method having insulin resistance and glycometabolism disorders.

The invention discloses an application of a lactalbumin-oleic acid composite to preparation of medicines for restraining energy metabolism of tumor cells, and finds that alpha-LA-OA can resist the glycolysis process of tumor cells and reduce the consumption of oxygen by an aerobic respiration process of a mitochondrion and the generation amount of ATP. In addition, the invention further finds thatthe alpha-LA-OA can reduce generation of ATP in an HepG2 cell glucose metabolism way, so that the effect of restraining energy metabolism of tumor cells can be achieved; an HepG2 tumor cell model isused for confirming that the alpha-LA-OA can notably promote expression of mTORC2 target protein Rictor, mSin1 and Ser473-Akt, and the expression amount of various enzymes in the glycolysis way can benotably reduced. The alpha-LA-OA can activate an mTORC2 signal route, and can restrain activity of key enzymes in the glucose metabolism way, so as to reduce the energy metabolism for restraining tumor cells, by ATP.

A composition, including: (A) Panax notoginseng; and at least one of (B) a Piper longum extract and (C) vitamin B1, a salt thereof or a derivative thereof.

The present invention provides novel cell-based and animal-based assays for determining antagonists of PKCε and uses of the isolated antagonist compounds for modulating insulin clearance and secretion. The invention also provides novel animals and cells such as animals and cells suitable for use in the assays.

The invention relates to the use of a Streptococcus thermophilus strain with a deficiency in glucose metabolism for improving growth of a Lactobacillus strain in a process for producing a fermented milk product.

Disclosed is an enzyme composition for regulating sugar metabolism which can regulate the absorption of glucose into the body by converting the carbohydrates in food to a form of sugar that is not absorbed in the stomach and the like before being decomposed in the small intestine into glucose by the activity of various enzymes such as maltase, sucrase, or lactase and the like and absorbed, wherein the enzyme composition includes: one or more enzymes selected from the group consisting of glucoamylase, sucrase and lactase; glucose oxidase; and transglucosidase.

The invention discloses a monoclonal antibody resistant to vole babesia. The monoclonal antibody is secreted by a hybridoma cell strain HA5-E4 having a collection number of CCTCC NO: 201835. Aiming atlactic dehydrogenase LDH in a glucide metabolic pathway of the vole babesia, the protein has immunogenicity, and a monoclonal antibody aiming at rBmLDH is prepared; Western blot detection proves thatthe monoclonal antibody is capable of specifically recognizing the vole babesia but cannot recognize the LDH of the host. Therefore, the monoclonal antibody can be applied to detection of vole babesia in infection cells through an immumofluorescence method.

The invention relates to the technical field of gene therapy or biological medicine, in particular to a nucleic acid construct for gene therapy of glycometabolism-related diseases; the nucleic acid construct comprises polynucleotide for coding GLP-1 or an analogue thereof; the total number of the GLP-1 or the analogue thereof is more than two; the GLP-1 and the GLP-1 are connected through polynucleotide for coding a connecting peptide; the GLP-1 and the analogue thereof are connected through the polynucleotide for coding the connecting peptide; or the analogue of the GLP-1, the GLP-1 and the analogue are connected through the polynucleotide for coding the connecting peptide. The nucleic acid construct disclosed by the invention can be used for efficiently expressing the GLP-1 with the activity and the analogue thereof in vivo and in vitro, so that a technical route is provided for developing medicines for treating glycometabolism-related diseases such as type 2 diabetes, body metabolic disorder, diabetes-related complications and obesity which have great potential.

The invention discloses a sugar control composition containing quinoa and preparation method thereof. The preparation method comprises the following steps: respectively weighing the following components in percentage by mass: 25-40% of quinoa, 10-20% of purple rice, 10-20% of white kidney beans, 10-20% of oats and 10-20% of walnuts, the sum of the mass percentages of the components being 100%; in the formula, vitamin B1 in the quinoa and coarse cereals in the formula can maintain normal glycometabolism and nerve conduction functions of diabetic patients, and can help diabetic patients to maintain capillary health and avoid microangiopathy; so that the composition is capable of improving the kidney cell metabolism disorder caused by hypertension, wherein magnesium can better help the blood sugar of the diabetic patient to be converted into energy, and meanwhile insulin response is improved. In addition, the n-3 series of polyunsaturated fatty acids in the walnuts can help and enhance cell activity, then increase insulin receptors, make insulin very sensitive, increase blood sugar consumption and convert blood sugar into glycogen.

The invention discloses a method for preparing a Kinase protein Akt1 conditional gene knockout non-human mammal model and application of the method. The invention further discloses a method for screening compounds for preventing or treating cardiomegaly and glucose metabolic disorders by the Kinase protein Akt1 conditional gene knockout non-human mammal model, and application of the model that Akt1 and upstream and downstream biological signal transduction pathways of the Akt1 serve as medicine intervention targets to treat cardiomegaly and glucose metabolic disorders.

The invention discloses an application of epimedin C in prevention and treatment of acute alcoholism, and belongs to the technical field of biological medicine. The invention discloses that the epimedin C can shorten the sobering time and sleepiness time of an acute alcoholism model animal, prolong the drunkenness latency period, reduce the levels of total bilirubin, total cholesterol and triglyceride in serum, reduce the activity levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in serum, increase the content of reduced glutathione, reduce the content of malondialdehyde, can maintain normal forms and structures of liver tissues and cells, regulate proteome expression of acute alcoholism animals, repair damage of nervous systems, improve oxidative stress states of organisms and improve glycometabolism and lipid metabolism, so that the epimedin C can be used for preparing drugs for preventing and treating acute alcoholism. The epimedin C is used for preparing a medicine for preventing and treating acute alcoholism in the form of a medicinal preparation such as aerosol and the like. The invention is helpful for promoting the research and development process of acute alcoholism prevention and treatment medicines, and also provides a thought for development and utilization of epimedium resources.

The invention relates to the technical field of animal model establishment, in particular to a non-alcoholic fatty liver animal model and an establishment method. The animal model is established by adopting an NR4A1- / -gene knockout mouse. The NR4A1- / -gene knockout mouse is adopted to establish the non-alcoholic fatty liver animal model, the relationship between the NR4A1- / -gene and glycometabolism and fat metabolism of the liver is fully utilized, the glycolipid metabolism of the NR4A1- / -gene knockout mouse is disturbed, and fat can be deposited on the liver after high-fat feeding, so that the non-alcoholic fatty liver is formed; the method is simple to operate and obvious in effect. The animal model has the characteristics of obesity, dyslipidemia and the like, and has high similarity with NAFLD clinical pathology.